Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial assessing lorlatinib together with local consolidation therapy for patients with ALK-positive advanced non-small ce…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study [NA]
A pilot clinical trial evaluating a precise exercise regimen for cancer care in patients with non-small cell lung cancer; the study is not y…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors [Phase 1, Phase 2]
Phase 1/2 dose-finding study evaluating safety, pharmacokinetics, and dose optimization of a new therapy in advanced refractory solid tumors…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of intravenous QEQ278 in patients with advanced solid tumors has been terminated.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of BL0020 injection for small cell lung cancer transformed from non-small cell lung c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating tuvusertib in combination with cemiplimab for non-small cell lung cancer is currently active and not recruiting…
-
FDA approval · 2026-02-13FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)
FDA approved the original biologics license for Rybrevant Faspro, a subcutaneous formulation of amivantamab with hyaluronidase-lpuj, develop…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 neoadjuvant trial is evaluating the combination of an anti-CTLA-4 antibody with Sintilimab and chemotherapy for resectable stage I…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy [Phase 2]
This clinical trial update describes a phase 2 study in which ctDNA monitoring guides the use of Befotertinib plus radiotherapy for advanced…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: First in Human Study of TORL-1-23 in Participants With Advanced Cancer [Phase 1]
TORL Biotherapeutics announced a first-in-human Phase 1 trial of TORL-1-23 for advanced cancers. The study is currently recruiting and inclu…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
This ClinicalTrials.gov entry describes a study by A2 Biotherapeutics evaluating HLA LOH analysis and apheresis for CAR-T cell manufacturing…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer [Phase 1]
A Phase 1 clinical trial update evaluating the combination of All-Trans Retinoic Acid (ATRA) and atezolizumab for recurrent or metastatic no…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors [Phase 1]
Phase I trial comparing HLX17 to Keytruda in multiple solid tumors to evaluate pharmacokinetics, preliminary efficacy, safety, and immunogen…
-
CLINICAL_TRIALS other · 2026-02-13Clinical Trial Update: IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial update on IBI363 combined with chemotherapy as neoadjuvant therapy for initially unresectable stage III non-small cel…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) [Phase 2]
Clinical trial update for RP1 as a monotherapy and in combination with nivolumab (IGNYTE) in Phase 2 across several cancers; the study is cu…
-
EMA approval · 2026-02-12EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Retsevmo (selpercatinib) for RET fusion-positive cancers in the EU, including non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases [Phase 3]
A Phase 3 trial evaluating furmonertinib plus platinum-based chemotherapy versus osimertinib in patients with EGFR-sensitizing mutation-posi…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation [Phase 1]
Phase 1 study to evaluate safety, pharmacokinetics, and activity of GDC-6036 alone or in combination in participants with KRAS G12C-mutant a…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A Phase 1/2 trial of Rucaparib plus Pembrolizumab as maintenance therapy in Stage IV non-squamous non-small cell lung cancer was terminated,…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study [Phase 2]
A Phase 2 trial (The Knight SHIFT Study) is comparing morning versus afternoon administration of immunotherapy for advanced or metastatic so…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating local ablative therapy for oligometastatic lesions in EGFR-mutated non-small cell lung cancer, currently r…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation [Phase 3]
A Phase 3 trial is evaluating firmonertinib versus platinum-based chemotherapy as first-line treatment for advanced non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [Phase 1]
A Phase 1 trial studied the combination of palbociclib and binimetinib in patients with advanced KRAS-mutant non-small cell lung cancer; the…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
This entry describes a Phase 2 clinical trial evaluating cemiplimab plus chemotherapy, comparing a standard combination with an augmented re…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy [Phase 2]
Phase 2 clinical trial evaluating diclofenac in patients with metastatic non-small cell lung cancer who are receiving single-agent immunothe…